MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2017 International Congress

    Does levodopa-carbidopa intestinal gel in Parkinson’s disease patients increase the risk on polyneuropathy?

    H. Moes, M. Drent, T. Laar (Groningen, Netherlands)

    Objective: To analyze the influence of the overall levodopa exposure on the risk of polyneuropathy (PN) in levodopa-carbidopa intestinal gel (LCIG)-infusion treated patients with Parkinson’s…
  • 2017 International Congress

    Patient perspectives of using the ND0612 mini-pump

    S. Nash, M. Gera, E. Shor, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

    Objective: To evaluate patient and caregiver usability and satisfaction with the mini-pump that will be used for continuous ND0612 delivery among patients with moderate-severe PD.…
  • 2017 International Congress

    Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Buenos Aires, Argentina)

    Objective: To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson’s Disease (PD) patients and to assess the factors related…
  • 2017 International Congress

    Decision making under uncertainty in medicated and un-medicated Parkinson’s disesase

    J. Corrow, M. Cherkasova, A. Taylor, J. Stoessl, M. McKeown, S. Apple Creswell, J. Barton (Vancouver, BC, Canada)

    Objective: To evaluate decision making under risk in Parkinson’s disease patients, both medicated and un-medicated states probing constituent cognitive operations driving choice.  Background: Prior literature…
  • 2017 International Congress

    ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD

    N. Giladi, Y. Caraco, T. Gurevich, R. Djaldetti, L. Adar, T. Rachmilewitz Minei, S. Oren (Tel Aviv, Israel)

    Objective: Characterize the levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612. Background: Continuous levodopa/carbidopa (LD/CD) infusion is considered the optimal delivery route…
  • 2017 International Congress

    Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions

    C. Lee, E.J. Choi, S.-C. Park, J.K. Lee (Seoul, Republic of Korea)

    Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…
  • 2017 International Congress

    Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease

    B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas (Ribeirão Preto, Brazil)

    Objective: To identify genetic risk factors for developing levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD). Background: LID are common complications in PD, but…
  • 2017 International Congress

    Identification of the optimal carbidopa concentration in subcutaneously administered ND0612

    L. Adar, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

    Objective: To identify the concentration of subcutaneous (SC) carbidopa (CD) that provides optimal bioavailability of a concomitant fixed concentration of levodopa (LD) when administered via…
  • 2016 International Congress

    The influences of STN-DBS and levodopa on cardiovascular autonomic function in patients with Parkinson’s disease: Evaluated by trigonometric regressive spectral analysis

    K. Li, M. Wolz, R. Haase, H. Reichmann, T. Ziemssen (Dresden, Germany)

    Objective: To explore the effects of STN-DBS and levodopa on cardiovascular autonomic function in PD. Background: Cardiovascular autonomic dysfunction has been shown in patients with…
  • 2016 International Congress

    Changes in serum amino acid levels with progression of Parkinson’s disease

    M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

    Objective: The purpose of this study was to analyze changes in serum amino acid profile with progression of Parkinson's disease (PD). Background: PD is a…
  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley